Abstract: 【Abstract】 Objective To investigate the clinical efficacy and adverse reaction by implement of abdominal hot perfusion chemotherapy on advanced colorectal cancer after laparoscopic radical resection. Methods Seven- eight cases of advanced colorectal cancer patients were recruited and assigned to two groups，39 cases in each group. The patients in combined chemotherapy group underwent laparoscopic radical colorectal cancer resection combined with intraperitoneal hyperthermic chemotherapy（IPHC）for 3 times after surgery，then received the conventional systemic chemotherapy（XELOX），and those in single chemotherapy group were performed systemic chemotherapy alone in 4 weeks after laparoscopic radical colorectal cancer resection. The clinical efficacy and safety were evaluated in patients of two groups. KPS score，adverse reaction，survival rate were recorded and analyzed. Results The KPS score increased at a rate of 53.85% in combined chemotherapy group，and 25.64% in single chemotherapy group. The difference between two groups had statistical significance（P<0.05）. There was no difference between two groups in incidence of the adverse reaction. The 1-year，3-year and 5-year survival rates were respectively 92.31%，64.10% and 46.15%. The 3-year and 5-year survival rates were rising when compared with single chemotherapy group（all P values less than 0.05）. Conclusion For advanced colorectal cancer patients, IPHC supplementation based on systemic chemotherapy generally provides improvement in survival after laparoscopic radical resection，and had less adverse reactions during chemotherapy.

Key words: intraperitoneal hyperthermic chemotherapy, combined chemotherapy, advanced colorectal cancer, systemic chemotherapy

摘要： 【摘要】 目的 评估进展期结直肠癌患者在行腹腔镜下根治性切除术后采取腹腔热灌注 化疗联合全身化疗的临床疗效及安全性。方法 选择两组在我院收治的78例进展期结直肠癌 患者，一组为联合化疗组（39例），在行腹腔镜下结直肠癌根治性切除术后，首先行腹腔热灌注化 疗（IHIPC）3次，然后再采用全身化疗，方案为（XELOX）；另一组为单一化疗组（39例），在行腹腔 镜下结直肠癌根治性切除术后，单纯采用全身化疗，方案为（XELOX）。对两组患者的临床疗效 及安全性进行对比分析。结果 联合化疗组患者在化疗后，其KPS评分升高率为53.85%, 单一 化疗组在化疗后，其KPS评分升高率为25.64％，两者差异存在统计学意义（P<0.05）；两组患者的 各种不良反应发生率无明显差异（P>0.05）；对两组患者术后随访5年，联合化疗组的患者在第1、3、5 年的生存率分别为 94.87％、84.62％、69.23％，单一化疗组分别为92.31%、64.10%、46.15%，两组患者在第3、5年的生存率进行比较，其差异存在统计学意义（P<0.05）。结论 进展期结直肠癌患者在行腹腔镜下根治性切除术后采取腹腔热灌注化疗联合全身化疗，可能提高了患者的术后生存质量及生存率，且不良反应也无明显增加。

关键词: 进展期结直肠癌, 腹腔热灌注化疗, 联合化疗, 全身化疗